Fluorescent in situ hybridization as a screening test for HER2 amplification in G2 and G3 breast cancers of lobular and ductal histotype and metastases

Oncology Reports

Volumn 19, Issue 5, 2008, Pages 1271-1275

  Castellano, Isabella ^a   Sapino, Anna ^a   Arisio, Riccardo ^b   Viale, Giuseppe ^c   Bussolati, Gianni ^a   Bandelloni, Roberto ^d   Barresi, Gaetano ^e   Bersiga, Alessandra ^f   Bordi, Cesare ^g   Botti, Gerardo ^h   Cosimi, Fabia ⁱ   D'Amore, Emanuele ^j   Doglioni, Claudio ^k   Marchetti, Antonio ^l   Nappi, Oscar ^m   Romeo, Francesco ⁿ   Roncalli, Massimo ^o   Russo, Rosa ^p   Santinelli, Alfredo ^q   Spagnoli, Luigi Giusto ^r   Tanda, Francesco ^s   Tricomi, Paolo ^t   Trentini, Gianpaolo ^u   Zanconati, Fabrizio ^v   Iurlaro, Monica ^w   more..

^a UNIVERSITY OF TURIN   (Italy)

^b Sant'Anna Hospital   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f CREMONA HOSPITAL   (Italy)

^g UNIVERSITY OF PARMA   (Italy)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ OSPEDALI RIUNITI   (Italy)

^j Ospedale Civile   (Italy)

^k SAN RAFFAELE HOSPITAL   (Italy)

^l Ospedale di Chieti   (Italy)

^m CARDARELLI HOSPITAL   (Italy)

ⁿ Annunziata Hospital   (Italy)

^o UNIVERSITY OF MILAN   (Italy)

^p S Giovanni di Dio e Ruggi d'Aragona Hospital   (Italy)

^q UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^r UNIVERSITY OF ROME TOR VERGATA   (Italy)

^s UNIVERSITY OF SASSARI   (Italy)

^t A MANZONI HOSPITAL   (Italy)

^u UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^v UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^w Roche ^*  (Italy)

more..

Author keywords

Breast; Cancer; Effectiveness; Fluorescence in situ hybridisation; HER2; Metastases

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER GRADING; CANCER SCREENING; CENTRAL NERVOUS SYSTEM METASTASIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; INVASIVE CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE NEU; PLEURA METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SCREENING TEST; SKIN METASTASIS; TUMOR DIFFERENTIATION; BIOSYNTHESIS; CANCER INVASION; CANCER STAGING; FEMALE; GENETICS; MASS SCREENING; METHODOLOGY; MULTIVARIATE ANALYSIS; ONCOLOGY; PROTO ONCOGENE; REPRODUCIBILITY; STATISTICAL MODEL; TIME;

FEMALE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MASS SCREENING; MEDICAL ONCOLOGY; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 47549084286     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.5.1271     Document Type: Article

References (33)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
2. Press MF, Pike M, Chazin VR, et al: Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53: 4960-4970, 1993.
3. Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904, 1997.
4. Yamauchi H, Stearns V and Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19: 2334-2356, 2001.
5. Di Palma S, Collins N, Faulkes C, et al: Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. J Clin Pathol 60: 1067-1068, 2007.
6. Dybdal N, Leiberman G, Anderson S, et al: Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 93: 3-11, 2005.
7. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
8. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
9. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002.
10. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354: 809-820, 2006.
11. Yaziji H and Gown AM: Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome? Adv Anat Pathol 9: 338-344, 2002.
12. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145, 2007.
13. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131: 18, 2007.
14. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ and Weeks JC: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22: 854-863, 2004.
15. Hoff ER, Tubbs RR, Myles JL and Procop GW: HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol 117: 916-921, 2002.
16. Gong Y, Booser DJ and Sneige N: Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103: 1763-1769, 2005.
17. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
18. Taucher S, Rudas M, Mader RM, et al: Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer 98: 2547-2553, 2003.
19. Crowe JP, Patrick RJ, Rybicki LA, et al: A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. Breast 15: 728-735, 2006.
20. Bilous M, Ades C, Armes J, et al: Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 12: 92-98, 2003.
21. Lal P, Tan LK and Chen B: Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 123: 541-546, 2005.
22. Reis-Filho JS, Simpson PT, Jones C, et al: Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol 207: 1-13, 2005.
23. Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN and Merino MJ: Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 24: 1650-1656, 2000.
24. Frolik D, Caduff R and Varga Z: Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes, and tumor suppressor genes compared with invasive ductal carcinomas and infiltrating lobular carcinomas. Histopathology 39: 503-513, 2001.
25. Arpino G, Bardou VJ, Clark GM and Elledge RM: Infiltrating lobular carcinoma of the breast: tumour characteristics and clinical outcome. Breast Cancer Res 6: R149-R156, 2004.
26. Yaziji H, Goldstein LC, Barry TS, et al: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291: 1972-1977, 2004.
27. Owens MA, Horten BC and Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5: 63-69, 2004.
28. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K and Gattuso P: Correlation of Her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 11: 278-280, 2005.
29. Sloane JP, Amendoeira I, Apostolikas N, et al: Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch 434: 3-10, 1999.
30. Nadji M, Gomez-Fernandez C, Ganjei-Azar P and Morales AR: Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 123: 21-27, 2005.
31. Montemurro F and Aglietta M: The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 103: 1314-1315, 2005.
32. Beatty BG, Bryant R, Wang W, Ashikaga T, Gibson PC, Leiman G and Weaver DL: HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol 122: 246-255, 2004.
33. Daniele L, Macri L, Schena M, et al: Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther 6: 1223-1229, 2007.